Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Stock Information for 22nd Century Group Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 22nd Century Group Inc

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.